ImmunoCellular Therapeutics (AMEX:IMUC), Tuesday announced it has secured a Japanese patent for its technology for the treatment of brain cancer.
bio tech company, which is focused on immune-based cancer therapies,
already holds an exclusive, worldwide license for its lead product
candidate, ICT-107, a dendritic cell-based vaccine. Rather than simply
targeting a single tumor-specific antigen, the company's vaccine pursues
multiple different antigens found on cancer stem cells (CSCs).
said the patent covers the treatment of brain cancer with a combination
of a dendritic cell based vaccine combined either before or
concurrently with the administration of chemotherapy.
strengthening of our world-wide intellectual property protection for the
treatment and detection of cancers further supports our developmental
efforts and enhances our ability to license or partner our
immunotherapeutic platforms,” said president and CEO Manish Singh, Ph.D.
“It is with this in mind that we continue to pursue opportunities to solidify our intellectual property on a global scale.”
company said it believes that in the treatment of cancer, particularly
cancers of the central nervous system such as glioblastoma multiforme
(GBM), “a dual therapeutic approach that includes the administration of a
dendritic cell-based cancer vaccine combined with a regimen of
chemotherapy could substantially enhance the clinical efficacy of
is a Los Angeles-based clinical-stage company that is developing
immune-based therapies for the treatment of brain and other cancers.
this month the company announced the expansion of its current phase 2b
trial of ICT-107, in an effort to “further validate the study” and
possibly short the trial by a few months.
The bio tech firm said
that the trial will be expanded to include 123 patients, up from 102
that have either been treated or are scheduled to be randomized and
treated over the next few weeks with its ICT-107 vaccine.
phase 2 double-blind, placebo-controlled, randomized study is designed
to evaluate the safety and efficacy of the vaccine in patients with
newly diagnosed GBM.